Mitotherapeutix
Research ServicesConnecticut, United States2-10 Employees
Mitotherapeutix was created to take advantage of advancements in RNA chemistry and its use in developing new drugs (siRNA) which can target “undruggable” disease targets.
Niche Innovation Mitotherapeutix specializes in RNA chemistry for developing targeted therapies against traditionally undruggable disease markers, indicating significant potential for partnerships with biotech firms seeking innovative drug development solutions.
Growing Revenue With estimated revenues between 1 million and 10 million dollars and a small team, the company presents an agile, emerging opportunity for service providers looking to support early-stage biotech startups.
Funding Opportunity The absence of publicly listed funding suggests potential opportunities for investment or strategic collaborations to support its research advancements and scale operations.
Tech Infrastructure Utilizing common web technologies and cloud hosting services, Mitotherapeutix maintains a modern digital presence, which can facilitate easy engagement and outreach for technology and research service providers.
Market Positioning In comparison to larger competitors like Alnylam Pharmaceuticals, Mitotherapeutix operates in a specialized niche within RNA therapeutics, making it a promising partner for innovative biotech and research service collaborations.
Mitotherapeutix uses 8 technology products and services including WordPress, oEmbed, imagesLoaded, and more. Explore Mitotherapeutix's tech stack below.
| Mitotherapeutix Email Formats | Percentage |
| FLast@mitotherapeutix.com | 100% |
Research ServicesConnecticut, United States2-10 Employees
Mitotherapeutix was created to take advantage of advancements in RNA chemistry and its use in developing new drugs (siRNA) which can target “undruggable” disease targets.
Mitotherapeutix's revenue is estimated to be in the range of $1M$10M
Mitotherapeutix's revenue is estimated to be in the range of $1M$10M